Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoide Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
EudraCT-Number: 2015-003335-35
Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoide Arthritis
EudraCT-Number: 2015-003334-27
Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoide Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
EudraCT-Nummer: 2015-003332-13
Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoide Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
EudraCT-Nummer: 2015-003333-95
Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoide Arthritis With Inadequate Response to MTX
EudraCT-Nummer: 2015-003376-75